UK Offers NHS on Discount Rack for US Pharma Deals
Bloomberg’s headline heralds a 'drug pricing deal' where the UK will supposedly 'cut rebates paid to NHS,' easing tariff-free imports to the US for pharmaceutical giants. What this whitewashed language actually means is the British public, through their NHS, will pay disproportionately more for drugs, subsidizing lower costs for American consumers. It's not a deal; it's a structural transfer of
wealth from British taxpayers to US pharmaceutical companies, all wrapped up as bilateral cooperation. This isn't just about 'making friends' with Trump; it’s a long-standing demand from US trade negotiators to erode the NHS's ability to negotiate down drug prices, a core feature that keeps UK healthcare affordable compared to its American counterpart. The US has demanded access to the UK's
healthcare market for years, and now, it appears the NHS is finally on the chopping block to facilitate 'free trade' (for American Big Pharma, that is). Funny how 'free trade' always seems to involve dismantling public services in favor of corporate profits.